# Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone

> **NCT04167514** · PHASE3 · COMPLETED · sponsor: **CSL Behring** · enrollment: 136 (actual)

## Conditions studied

- Graft Versus Host Disease (GVHD)

## Interventions

- **BIOLOGICAL:** Alpha-1 antitrypsin (AAT)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04167514
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-09
- **Primary completion:** 2023-09-11
- **Final completion:** 2024-06-26
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2025-08-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04167514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04167514, "Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT04167514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*